AMGEN at AHA Annual Meeting

AHA Scientific Sessions 2023

November 11-13, 2023 | Philadelphia, PA

Cardiovascular & Metabolic Pipeline

Cardiovascular and Metabolic Clinical Trials Interactive

Learn about Amgen's pipeline clinical trials in ASCVD and obesity

Visit Interactive Resource

PROFICIO Booklet

Learn about PROFICIO, Amgen's program of clinical studies of evolocumab

View Booklet

PROFICIO Real-World Evidence Booklet

Learn about PROFICIO RWE, Amgen’s program of real-world evidence studies.

View Booklet

VESALIUS-CV

Effect of Evolocumab in patients at high CV risk without prior MI or Stroke. This is an investigational study.^†

View Clinical Trial Card

EVOLVE-MI

Trial of Evolocumab Administered Very Early in Patients Hospitalized with Acute MI

View Clinical Trial Card

OCEAN(a) Outcomes

Olpasiran Trials of Cardiovascular Events and Lp(a) Reduction. Olpasiran is an investigational drug.^*

View Clinical Trial Card

Maridebart Cafraglutide Phase 2

Dose ranging study of AMG 133 in adults with overweight or obesity with or without T2DM. AMG 133 is an investigational drug.^*

View Clinical Trial Card

^*Safety and efficacy have not been established.
^†Evolocumab is not indicated for this intended use.

ASCVD: Atherosclerotic cardiovascular disease, CV: Cardiovascular, MI: Myocardial Infarction, RWE: Real World Evidence, T2DM: Type 2 Diabetes Mellitus